Jade Biosciences, Inc. (JBIO)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
20.84 USD
-0.45
(-2.114%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 20.84 |
Hot Take ↕ | Aug. 22, 2026, 6:06 a.m. EDT
The immediate outlook is driven by a massive disconnect between the company's deteriorating reality and aggressive speculative buying. While the long-term picture is dire—marked by a catastrophic 98% price collapse over four years and three consecutive years of negative returns—the short-term momentum is building on a wave of new call flow. Investors are ignoring the negative earnings, the cash burn, and the fact that the stock is trading at a negative forward P/E, betting instead on a potential catalyst or a short squeeze given the high short ratio. This creates a high-risk, high-reward scenario suitable only for traders looking for a quick bounce, not investors seeking value. The dividend is a one-off event rather than a sustainable income stream, further confirming the speculative nature of the current price action. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.107884 |
| AutoTheta | 0.233351 |
| AutoARIMA | 0.292752 |
| MSTL | 0.315155 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.082 |
| Excess Kurtosis | -0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2025-04-28 |
| Debt to Equity Ratio | 0.316 |
| Market Cap | 1,325,369,600 |
| Forward P/E | -7.83 |
| Website | https://jadebiosciences.com |
As of Aug. 22, 2026, 6:06 a.m. EDT: Speculators are aggressively positioning for a rally, evidenced by heavy call volume and open interest at strikes above the current price, particularly the 17.5 strike where new flow exceeds existing inventory. Conversely, put activity is virtually non-existent, indicating a lack of hedging demand and a speculative bias toward upside moves despite the company's precarious fundamentals.
| Date | Dividend | Yield % |
|---|---|---|
| 2025-04-29 | 2.4 | 23.668638 |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.7939632 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 1,134.525 |
| All Time Low | 6.565 |
| Ask | 26.94 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 706,670 |
| Average Daily Volume3 Month | 1,130,695 |
| Average Volume | 1,130,695 |
| Average Volume10Days | 706,670 |
| Bid | 20.74 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 6.922 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.84 |
| Current Ratio | 14.927 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 21.4 |
| Day Low | 20.81 |
| Debt To Equity | 0.316 |
| Display Name | Jade Biosciences |
| Dividend Date | 1,745,798,400 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -164,702,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.255 |
| Enterprise Value | 865,555,520 |
| Eps Current Year | -2.93236 |
| Eps Forward | -2.66261 |
| Eps Trailing Twelve Months | -1.05 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.2528 |
| Fifty Day Average Change | -0.41279984 |
| Fifty Day Average Change Percent | -0.019423315 |
| Fifty Two Week Change Percent | 179.39632 |
| Fifty Two Week High | 28.0 |
| Fifty Two Week High Change | -7.16 |
| Fifty Two Week High Change Percent | -0.25571427 |
| Fifty Two Week Low | 6.91 |
| Fifty Two Week Low Change | 13.93 |
| Fifty Two Week Low Change Percent | 2.015919 |
| Fifty Two Week Range | 6.91 - 28.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,059,800,000 |
| Float Shares | 51,973,057 |
| Forward Eps | -2.66261 |
| Forward P E | -7.8269067 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 55 |
| Fullday Change | -0.450001 |
| Fullday Change Percent | -2.11367 |
| Fullday Price | 20.84 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00794 |
| Held Percent Institutions | 1.15931 |
| Implied Shares Outstanding | 63,597,387 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,745,884,800 |
| Last Dividend Value | 2.4 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,884,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts. |
| Long Name | Jade Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,325,369,600 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1889513328 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -124,442,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,354,624,343 |
| Number Of Analyst Opinions | 8 |
| Open | 21.04 |
| Operating Cashflow | -123,510,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 781 312 3013 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 20.84 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 21.29 |
| Price Eps Current Year | -7.106904 |
| Price Hint | 2 |
| Price To Book | 3.0106907 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.609 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.450001 |
| Regular Market Change Percent | -2.11367 |
| Regular Market Day High | 21.4 |
| Regular Market Day Low | 20.81 |
| Regular Market Day Range | 20.81 - 21.4 |
| Regular Market Open | 21.04 |
| Regular Market Previous Close | 21.29 |
| Regular Market Price | 20.84 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 357,915 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 63,597,387 |
| Shares Percent Shares Out | 0.1517 |
| Shares Short | 9,650,429 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,528,320 |
| Short Name | Jade Biosciences, Inc. |
| Short Percent Of Float | 0.1857 |
| Short Ratio | 11.1 |
| Source Interval | 15 |
| State | MA |
| Symbol | JBIO |
| Target High Price | 77.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 50.125 |
| Target Median Price | 47.0 |
| Total Cash | 461,204,992 |
| Total Cash Per Share | 7.252 |
| Total Debt | 1,389,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.701225 |
| Two Hundred Day Average Change | 3.1387749 |
| Two Hundred Day Average Change Percent | 0.17731965 |
| Type Disp | Equity |
| Volume | 357,915 |
| Website | https://jadebiosciences.com |
| Zip | 2,453 |